Background {#Sec1}
==========

Chiari was the first to describe the development of panniculitic lesions in patients with pancreatitis in 1883 \[[@CR1]\]. Since then, several case reports and small case series have reported focal or generalized panniculitis in association with pancreatic diseases like acute or chronic pancreatitis, pancreatic carcinoma (ductal adenocarcinoma, acinar cell carcinoma, neuroendocrine carcinoma) or intraductal papillary mucinous neoplasm (IPMN) \[[@CR2]--[@CR6]\].

Up to 45 % of patients with pancreatic panniculitis show subcutaneous panniculitic nodules before the causal disease is recognized \[[@CR2]\]. Therefore, these nodules can serve as an early and valuable clue to diagnosis of the underlying condition and trigger measurement of serum pancreatic enzymes, abdominal imaging or biopsy procedures. Histologic evaluation of the cutaneous lesions will typically reveal lobular neutrophilic necrotizing panniculitis intermingled with specific necrotic anucleate adipocytes called "ghost cells" \[[@CR7]\].

The mechanism underlying the formation of panniculitic nodules in pancreatic panniculitis is poorly understood. However, it is commonly believed that systemically released pancreatic enzymes such as lipase and amylase cause distant lipolysis and fat necrosis with consecutive inflammatory reaction \[[@CR8]\]. This is supported by the finding that the necrotic tissue stains positive for lipase \[[@CR9]\]. However, serum levels of pancreatic enzymes do not correlate with clinical findings and similarly, in vitro experiments suggest that this explanation is not sufficient \[[@CR10]\].

In addition to the cutaneous manifestation, arthritis is often found in patients with pancreatic panniculitis, clinically referred to as pancreatitis panniculitis polyarthritis (PPP) syndrome. It is thought that pancreatic enzymes are also able to trigger necrosis and inflammation in the synovium \[[@CR11]\]. Furthermore, there are reports about panniculitis in the bone marrow, at submucosal sites or within the thoracic or peritoneal cavity \[[@CR2], [@CR11], [@CR12]\].

Acinar cell carcinoma (ACC) is a rare pancreatic malignancy, representing about 1 % of all primary pancreatic neoplasms \[[@CR13]\]. ACC is the most common malignancy found in patients with pancreatic panniculitis \[[@CR14]\] and symptoms of pancreatic panniculitis can be found in up to 16 % of ACC patients \[[@CR4]\]. On very rare occasions, pancreatic-type ACC can also arise as a primary neoplasm at extrapancreatic locations, such as liver, stomach, jejunum and colon \[[@CR15]--[@CR18]\]. In such cases, extrapancreatic ACC is believed to originate from either ectopic, metaplastic of transdifferentiated pancreatic tissue and shares biologic features with primary pancreatic ACC \[[@CR15]\].

Here, we report the first case of pancreatic panniculitis in association with a primary pancreatic-type ACC of the liver without underlying pancreatic disease. Moreover, we present a review of case reports and case series of pancreatic panniculitis from the last 20 years, summarizing important knowledge and data about this disease entity.

Case presentation {#Sec2}
=================

A 73-year-old Caucasian female patient was referred to our department for further work-up of painful cutaneous lesions (Fig. [1](#Fig1){ref-type="fig"}) and several masses within her liver.Fig. 1Several panniculitic lesions on the right leg of the patient, one of them (→) shortly after having spontaneously drained brownish-oily fluid

Eight weeks prior, she had observed an erythematous nodule on her right chest. Subsequently, similar cutaneous lesions had developed on her arms and legs, and later also on her buttocks and back. She did not report any abdominal complaints. Outpatient treatment with topical and systemic steroids based on a suspicion of erythema nodosum (EN) did not yield substantial effect.

Four weeks prior, several liver lesions had been detected by ultrasound and were interpreted as metastases of a previously treated breast cancer. Additional imaging with computed tomography (CT) and magnetic resonance imaging (MRI) had been carried out (Fig. [2](#Fig2){ref-type="fig"}) and confirmed the liver lesions.Fig. 2Imaging of the liver lesions (→) with ultrasound (**a**) and CT (**b**)

As the nodules on her skin continued to spread and became increasingly painful, she was presented to the Department of Dermatology in our clinic. There, another attempt of steroids and an intensified local therapy resulted in no improvement of her clinical condition. Due to raising inflammatory parameters a work-up for possible infectious causes and an antibiotic therapy with piperacillin/tazobactam, and later with meropenem were initiated. A colonoscopy revealed two small polyps, which were completely removed. Pancreatic enzymes were markedly elevated. A punch biopsy of one of the skin lesions was obtained showing a lobular necrotizing panniculitis with "ghost cells" compatible with pancreatic panniculitis (Fig. [3](#Fig3){ref-type="fig"}). CT, MRI and repeated ultrasound examinations (Fig. [4](#Fig4){ref-type="fig"}) did not reveal any pathological findings in the pancreas. In contrast enhanced CT multiple sharply-bounded liver lesions were visualized in both liver lobes. Compared with the CT obtained during outpatient care, the lesions had progressed in size and measured from 1 cm to 6 cm. The perfusion pattern was non-hypervascular and the density was hypointense, partly comparable with the density of water. No necrotic areas were described within the lesions.Fig. 3Biopsy from a skin lesion showing lobular neutrophilic, necrotizing panniculitis and so called "ghost cells" (→)Fig. 4Abdominal imaging showing no evidence of pancreatic pathology. **a** CT. **b** MRI. **c** ultrasound

Because of a progressive worsening of her clinical condition and increasing laboratory markers of inflammation, the patient was referred to our Department of Internal Medicine. She complained about intensive pain all over her skin and required increasing dose rates of opioid analgetics. She did not report any weight loss, night sweats, fever, nausea or vomiting, abdominal pain or problems with food intake. Her past medical history was remarkable for invasive ductal breast cancer diagnosed in 1982 with local recurrences in 1990 and 2008. Moreover, a superficial spreading malignant melanoma had been treated in 2011 and a coronary artery disease with percutaneous coronary intervention in 2008 was reported. Family history was significant for malignant melanomas in all siblings and her mother. Continuous medication included acetyl salicylic acid, lercanidipine, metoprolol, enalapril and pravastatin with no recent change. No allergic condition was known.

On examination she was in poor general condition (ECOG performance status 4), tachycardic (102 bpm), slightly tachypnoeic (22/min) and normotensive (128/78 mmHg). Her temperature was 36.9 °C. Subcutaneous erythematous and painful nodules of 2--5 cm size were noticed throughout her integument. Some of them were spontaneously draining a brownish oily fluid. Moreover, more than 200 melanocytic nevi were observed on her skin. Examination of the head, especially focusing on the salivary glands was unremarkable. There was no pain on abdominal palpation, the liver was palpable 2 cm under the right costal arch and bowel sounds were normal. There was a positive tap sign on both patellae.

Laboratory results of interest were: leukocyte count 21.5 \* 10\^3/μl (ref. 4--10 \* 10\^3/μl), hemoglobin 10.0 g/dl (ref. 12--16 g/dl), ASAT 52 U/l (ref. \< 35U/l), GGT 235 U/l (ref. \<40 U/l), AP 186 U/l (ref. 35--105 U/l), lipase 14747 U/l (ref. \< 60 U/l) and CRP 237 mg/l (ref. \< 5 mg/l). Alpha-Amylase, uric acid, ACE, CEA, CA19-9 and AFP were within normal range. Serology for Yersinia enterocolitica and pseudotuberculosis was negative, as well as testing for Mycobacterium tuberculosis and atypical mycobacteria. Rheumatologic testing including ANAs and ANCAs was unremarkable.

Screening for possible infectious foci did not reveal any other source explaining the elevated CRP. Therefore, it was attributed to the skin lesions, which displayed clinical signs of inflammation and were partly draining pus in the further course. However, as microbiological evaluation was not able to prove any causative organism and inflammation markers were not substantially declining despite escalation of antibiotic treatment with additional vancomycin, skin lesions were classified as sterile. Leukocytosis was explained by concomitant steroid therapy.

Ultrasound displayed several liver lesions in both lobes with a maximum size of 53 mm. The pancreas was homogeneous and free of focal lesions. The pancreatic duct was not dilated and no avascular areas could be detected upon administration of ultrasound contrast agent. Ultrasound-guided puncture of one of the liver masses was performed leading to the histopathological diagnosis of a pancreatic-type ACC.

Unfortunately, the condition of the patient had severely deteriorated in the meantime with further exacerbation of pain, increasing tachycardia and hypotension. Therefore, no tumor-specific treatment could be initiated. The patient died ten days after admission to our ward.

Pathological and autopsy findings {#Sec3}
---------------------------------

Histopathological analysis of the core biopsy obtained from the liver mass revealed a cellular epithelial neoplasm composed of monomorphic polygonal or rounded cells arranged in compact acinar and trabecular structures (Fig. [5a, b](#Fig5){ref-type="fig"}). Immunohistochemical study revealed strong expression of pancytokeratin (KL-1) with variable expression of CK7 and diffuse strong cytoplasmic expression of trypsin (Fig. [5c](#Fig5){ref-type="fig"}), but lipase and amylase were negative. All other markers in the differential diagnosis were negative (CK5, CK20, HepPar-1, Synaptophysin, Chromogranin A, NSE, CD56, TTF1, ER, PR, protein S100, GATA3 and PAX8). These findings including in particular the strong and specific expression of trypsin confirmed the diagnosis of pancreatic-type ACC in the liver.Fig. 5Histomorphology and immunohistochemistry of the liver tumor (from core biopsy). **a** core biopsy of the liver showing liver tissue adjacent to the acinar cell carcinoma, haematoxylin/eosin staining, 10-fold magnification. **b** compact acinar structures and trabeculae seen at higher magnification, haematoxylin/eosin staining, 40-fold magnification. **c** The tumor cells stained strongly for trypsin, 40-fold magnification

Autopsy confirmed several liver masses measuring up to six centimeters in size. There was no evidence of a salivary gland tumor or a primary pancreatic tumor. Additionally, review of the slides from the patient's previous breast cancer confirmed a breast cancer of no special type and excluded the possibility of acinar-like differentiation. Thus, the previous breast cancer was also unrelated to the patient\'s ACC. Cause of her death was attributed to multiorgan failure due to severe systemic inflammatory response syndrome.

Final diagnosis was pancreatic panniculitis due to primary pancreatic-type acinar cell carcinoma of the liver.

Taking into account the conspicuous accumulation of malignancies in our patient and her family, genetic analysis for familial atypical multiple mole-melanoma (FAMMM) syndrome was recommended to her relatives.

Review of literature {#Sec4}
--------------------

In addition to the presented case, 130 reports on pancreatic panniculitis were identified in the English literature between January 1994 and November 2014 by using the search terms "pancreatic panniculitis", "subcutaneous fat necrosis AND pancreas" and "lipase hypersecretion syndrome" in PubMed and by checking results for appropriate cross-references.

Including the above case, all 131 cases (Table [1](#Tab1){ref-type="table"}) were analyzed in respect to available data on age and gender of the patients, the underlying condition, additional symptoms, the sequence of the appearance of panniculitis and the diagnosis of the underlying disease, laboratory values and the outcome. The stated percentages refer to the respective number of cases including data on the analyzed parameter. Statistical analysis was performed with IBM SPSS Statistics (IBM, Armonk, NY, USA) using Student's T-test or Fisher's exact test where applicable. *p* \< 0.05 was considered significant. Graphs were generated with SigmaPlot (Systat, San Jose, CA, USA).Table 1Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014PatientRef.AgeSexUnderlying conditionOutcome of skin lesions/follow-up1our pat.73fACC of the liverdeath ten weeks after first skin lesion2\[[@CR53]\]55mmetastatic pancreatic NECn.r.3\[[@CR54]\]38macute pancreatitisresolution4\[[@CR7]\]63macute pancreatitisresolution5\[[@CR55]\]81fhemosuccus pancreaticusdeath 19 weeks after first skin lesion6\[[@CR56]\]26facute pancreatitisresolution7\[[@CR57]\]27facute pancreatitisresolution8\[[@CR58]\]34mchronic pancreatitisn.r.9\[[@CR59]\]63facute pancreatitisresolution10\[[@CR60]\]83mpancreatic ACCresolution of skin lesions after surgery, death 34 months after first skin lesion11\[[@CR60]\]75mAcute pancreatitisresolution12\[[@CR60]\]60mLarge pancreatic neoplasmn.r.13\[[@CR61]\]68fmetastatic pancreatic ACCdeath six months after first skin lesion14\[[@CR62]\]61facute pancreatitisresolution15\[[@CR63]\]63facute pancreatitisresolution16\[[@CR64]\]49macute pancreatitisresolution17\[[@CR47]\]69mhepatic metastasis of previous-ly resected pancreatic ACCresolution after metastasectomy, follow-up n.r.18\[[@CR65]\]71fchronic pancreatitis with pseudocystn.r.19\[[@CR66]\]66fserous cystadenoma of the pancreasn.r.20\[[@CR67]\]39mchronic pancreatitisdeath six weeks after first skin lesion21\[[@CR68]\]20fpseudopapillary pancreatic tumor, chronic pancreatitisdeath eleven weeks after first skin lesion22\[[@CR8]\]38facute pancreatitisresolution23\[[@CR69]\]56facute pancreatitisdeath within a few days24\[[@CR70]\]79mpancreatic ACCn.r.25\[[@CR71]\]17facute pancreatitisresolution26\[[@CR72]\]54mpancreatic ACCResponse to octreotide, regression of skin lesions after resection, follow-up two months (i.e. eleven months after first skin lesion)27\[[@CR73]\]81fpancreatic tumor with hepatic metastasesn.r.28\[[@CR74]\]64manastomotic leakage after Whipple proceduredeath 50 days after first skin lesion29\[[@CR75]\]79fpancreatic ACCregression after resection, follow-up 14 months after resection (i.e. 16 months after first skin lesion)30\[[@CR35]\]60fpancreatic adenocarcinoman.r.31\[[@CR35]\]58mmalignant neoplasia of the tail of the pancreasn.r.32\[[@CR76]\]44fpancreas transplant rejectionresolution33\[[@CR77]\]63fmetastatic pancreatic adenocarcinoman.r.34\[[@CR78]\]38mpancreatic pseudocyst-inferior vena cava fistularesolution after Roux-en-Y pseudocyst-jejunostomy35\[[@CR40]\]82mpancreatic ACCdeath 2.5 months after first skin lesion36\[[@CR46]\]79mpancreatic ACCdeath two months after first skin lesion37\[[@CR79]\]2,5macute pancreatitis with pseudocystn.r.38\[[@CR80]\]45mchronic pancreatitisresolution after placement of endoprothesis39\[[@CR81]\]18wacute pancreatitisresolution40\[[@CR82]\]10wacute pancreatitis with pseudocystresolution after endosonographic cysto-gastrostomy41\[[@CR83]\]69mgastric adenocarcinoma with pancreas metastasisdeath 14 weeks after first skin lesion42\[[@CR84]\]58mpancreatic pseudocyst-portal vein fistuladeath five days after admission43\[[@CR85]\]84mpancreatic tumordeath two months after first skin lesion44\[[@CR86]\]40mchronic pancreatitisn.r.45\[[@CR87]\]84facute pancreatitis, liver lesions ten years after resection of colonic carcinomainitially resolution, death three months later46\[[@CR2]\]65facute pancreatitisdeath from gangrenous cholecystitis47\[[@CR2]\]64facute pancreatitisresolution48\[[@CR2]\]70fpancreatic carcinomadeath49\[[@CR2]\]58mpancreatic carcinomadeath50\[[@CR2]\]21fpancreatic carcinomadeath51\[[@CR2]\]75macute pancreatitisdeath52\[[@CR2]\]75facute pancreatitisresolution53\[[@CR2]\]44mchronic pancreatitisresolution54\[[@CR2]\]63mpancreatic carcinomadeath55\[[@CR2]\]72mpancreatic carcinomadeath56\[[@CR2]\]60mpancreatic carcinoman.r.57\[[@CR88]\]35mchronic pancreatitisn.r.58\[[@CR89]\]7macute pancreatitisresolution59\[[@CR14]\]61mmetastatic NEC of unknown primary sitedeath a few weeks after first skin lesion60\[[@CR42]\]50fmetastatic ACCregression of skin lesions and tumor under octreotide, gemcitabine, streptozocin and doxorubicin; return after discontinuation; response to restart of therapy; follow-up 9 months after first skin lesion61\[[@CR90]\]74mpancreatic ACCdeath 3.75 months after first skin lesion62\[[@CR91]\]61mmetastatic ACCn.r.63\[[@CR92]\]79mmetastatic pancreatic NECRegression under cefazolin, dexamethasone and NSAID; death 13 months after first skin lesion64\[[@CR93]\]50macute pancreatitisdeath 38 days after first skin lesion65\[[@CR94]\]4macute pancreatitisresolution66\[[@CR11]\]45macute pancreatitisRegression under NSAID and prednisone67\[[@CR95]\]72macute pancreatitisresolution68\[[@CR96]\]52fpancreatic carcinomadeath six months after first skin lesion69\[[@CR97]\]29macute pancreatitisresolution70\[[@CR23]\]75fhepatic metastases of adeno-carcinoma of unknown origindeath 15 weeks after first skin lesion71\[[@CR6]\]78mmetastatic pancreatic NECdeath two months after first skin lesion72\[[@CR6]\]75mpancreatic adenocarcinomaregression under irradiation, follow-up n.r.73\[[@CR98]\]67fIPMNpartial pancreatectomy, follow-up n.r.74\[[@CR99]\]51mchronic pancreatitisregression of skin lesions under conservative treatment75\[[@CR100]\]49fpancreas transplant rejectionresolution76\[[@CR101]\]89facute pancreatitisresolution77\[[@CR42]\]59mhepatic metastases of pre-viously resected pancreatic ACCdeath several weeks after first skin lesion78\[[@CR102]\]67mmetastatic pancreatic adenocarcinomaregression under irinotecan, cisplatin, mito-mycin; death twelve months after first skin lesion79\[[@CR103]\]62fIPMNresection, follow-up n.r.80\[[@CR22]\]60mmetastatic pancreatic acinar cell cystadenocarcinomadeath seven weeks after admission81\[[@CR104]\]13mchronic pancreatitis with pseudocystregression after cystogastrostomy82\[[@CR41]\]72mpancreatic NECregression after resection, no reappearance with liver metastases, death 15 months after first skin lesion83\[[@CR25]\]58mHCCdeath four months after first skin lesion84\[[@CR105]\]88mmetastatic pancreatic NECDeath eight weeks after first skin lesion85\[[@CR106]\]42facute pancreatitisresolution86\[[@CR107]\]63mchronic pancreatitisresolution after distal pancreatectomy and pancreatic duct dilation87\[[@CR108]\]34macute pancreatitisresolution88\[[@CR109]\]21facute pancreatitisdeath from retroperitoneal hemorrhage89\[[@CR110]\]61fmetastatic pancreatic ACCdeath one year after first skin lesion90\[[@CR3]\]70fIPMNresolution after resection91\[[@CR3]\]53fIPMNresolution after resection92\[[@CR111]\]37facute pancreatitis with pseudocystresolution after surgery93\[[@CR111]\]50macute pancreatitis with pseudocystresolution after stone extraction from the pancreatic duct94\[[@CR112]\]71mpancreatic adenocarcinoman.r.95\[[@CR113]\]60fpancreatic ACCregression after distal pancreatectomy, follow-up 28 months after first skin lesion96\[[@CR113]\]54mpancreatic ACCdeath six weeks after first skin lesion97\[[@CR114]\]56mchronic pancreatitisn.r.98\[[@CR115]\]53mactue pancreatitisresolution99\[[@CR48]\]67mmetastatic pancreatic ACCRegression after TACE of four liver metasta-ses, death 14 weeks after first skin lesion100\[[@CR116]\]n.r.n.r.chronic pancreatitisresolution after placement of pancreatic duct stent101\[[@CR117]\]31macute pancreatitisresolution102\[[@CR118]\]57facute pancreatitisresolution103\[[@CR119]\]60fpancreatic ACCresolution after resection, follow-up n.r.104\[[@CR120]\]41macute pancreatitisdeath 22 days after admission105\[[@CR44]\]79fmetastatic pancreatic ACCDeath 20 weeks after first skin lesion106\[[@CR121]\]45mchronic pancreatitisresolution107\[[@CR122]\]59facute pancreatitisresolution108\[[@CR123]\]81mpancreatic ACCn.r.109\[[@CR124]\]69mpancreatic ACCn.r.110\[[@CR125]\]15facute pancreatitisdeath nine days after first skin lesion111\[[@CR126]\]49macute pancreatitisregression under antibiotic treatment, then slight progression, follow-up seven weeks112\[[@CR127]\]66mpancreatic ACCresolution after resection, follow-up n.r.113\[[@CR128]\]67mchronic pancreatitisdeath two months after first skin lesion114\[[@CR12]\]69mpancreatic ACCresolution after distal pancreatectomy and adjuvant radio-chemotherapy, follow-up 6 months115\[[@CR129]\]29facute pancreatitisresolution116\[[@CR130]\]29mpancreatic pseudocyst-portal vein fistulano new lesions after surgery117\[[@CR131]\]75mpancreatic tumorDeath several months after first skin lesion118\[[@CR131]\]39mchronic pancreatitis with pseudocystn.r.119\[[@CR132]\]62macute pancreatitisresolution120\[[@CR133]\]77fpancreatic tumordeath five months after first skin lesion121\[[@CR134]\]54fchronic pancreatitisresolution after ESWL and endoscopic dilation of the pancreatic duct122\[[@CR135]\]47facute pancreatitisresolution123\[[@CR136]\]7macute pancreatitisn.r.124\[[@CR137]\]69mchronic pancreatitis with pseudocystresolution125\[[@CR138]\]33facute pancreatitisn.r.126\[[@CR139]\]46fchronic pancreatitisdeath four months after first skin lesion127\[[@CR140]\]55mchronic pancreatitisn.r.128\[[@CR5]\]62macute pancreatitisresolution129\[[@CR141]\]61fmetastatic ACCresolution after surgery, follow-up n.r.130\[[@CR142]\]80mpancreatic ACCresolution after surgery, death from metastatic disease after 18 months131\[[@CR143]\]n.r.mpancreatic ACCn.r.

Overall, 65 cases (49.6 %) were due to acute or chronic pancreatitis and 60 cases (45.8 %) had an underlying neoplastic condition. In six cases (4.6 %) other reasons were present, e.g. pancreas transplant rejection or pancreaticovascular fistula (Table [2](#Tab2){ref-type="table"}).Table 2Etiology of pancreatic panniculitisPancreatitisNeoplastic conditionsOtherAcute34.4 %pancreatic ACC19.8 %fistula2.3 %Chronic15.3 %n. r.9.9 %transplant rejection1.5 %NEC4.6 %adeno-carcinoma3.8 %anastomotic leakage0.8 %IPMN3.1 %other4.6 %Total49.6 %total45.8 %total4.6 %While near half of the cases are caused by acute or chronic pancreatitis, another 45.8 % are associated with neoplastic conditions (other: acinar cystadenocarcinoma, ACC of the liver, serous cystadenoma, HCC, gastric carcinoma with pancreatic infiltration, adenocarcinoma of unknown primary)

Patients with pancreatic panniculitis had a mean age of 54.8 years. Yet, patients with neoplastic causes were significantly older than individuals with pancreatitis (Fig. [6a](#Fig6){ref-type="fig"}). 57.4 % of the patients were male with no difference in sex distribution between underlying pancreatitis and malignancy.Fig. 6Comparison of patients with pancreatitis and neoplasm underlying pancreatic panniculitis (**a**-**c**): **a** Patients with neoplastic conditions are significantly older than patients with pancreatitis (66.0 +/− 13.0 years vs. 44.7 +/− 20.5 years, *p* \< 0.001). **b** Underlying malignancy is diagnosed significantly later than underlying pancreatitis (134 +/− 135 days vs. 20 +/− 26 days, *p* \< 0.001). **c** Tumor patients have significantly higher lipase levels than pancreatitis patients (16611 +/− 20772 vs. 5324 +/− 14436 U/l, *p* \< 0.01). **d** Kaplan-Meier plot of survival after appearance of the first panniculitis lesion in patients with pancreatic panniculitis associated with malignancy. Median survival is 4.75 months (*n* = 29)

In 48.9 %, cutaneous lesions were noted prior to the diagnosis of the underlying disease. The mean duration from appearance of the first lesion to diagnosis was 85 days +/− 110 days (range: 2--540 days; median 42 days). This period was significantly longer when pancreatic panniculitis was due to a neoplasm than when a pancreatitis was present (Fig. [6b](#Fig6){ref-type="fig"}). Moreover, the portion of patients developing panniculitis before the diagnosis of the underlying condition was by trend higher in patients with neoplastic disease (66.7 %) than in patients with pancreatitis (48.3 %; *p* = 0.06).

A PPP syndrome with additional signs of arthritis was present in 49 cases (37.4 %).

One hundred twelve case reports (85.5 %) contained information on the serum levels of at least one pancreatic enzyme. In all but two of these reports (1.8 %) either amylase or lipase were elevated -- in one of these two cases only amylase had been measured. The mean level of lipase was 11560 U/l +/− 19010 U/l (range 7--89700 U/l, median 3942.5 U/l). Again, patients with pancreatitis and neoplastic conditions differed markedly with tumor patients having significantly higher lipase levels (Fig. [6c](#Fig6){ref-type="fig"}). ROC analysis identified a lipase level of 4414 U/l as best cut-off value with higher values having a sensitivity of 73.0 % and a specificity of 82.1 % for the diagnosis of a neoplastic cause (AUC = 0.785, 95 % CI 0.68 to 0.89).

Only limited data was available concerning survival and follow-up. 12 patients with pancreatitis (21.4 %) died from complications. For underlying malignancy, follow-up data was available for 29 patients. A Kaplan-Meier plot of survival was computed, yielding a median survival of 4.75 months after appearance of the first skin lesion (Fig. [6d](#Fig6){ref-type="fig"}).

Discussion {#Sec5}
----------

Panniculitis is a clinical finding, which can be caused by various etiologic factors including infectious, immunologic and neoplastic conditions \[[@CR19]--[@CR21]\].

In our case, numerous causes could be excluded, while others were very unlikely: No infectious organism could be detected directly or indirectly. Continuous medication was unchanged and unsuspicious for causing erythema nodosum. Imaging had not yielded any evidence of malignancy other than the finally diagnosed ACC. Rheumatologic disease was judged unlikely based on consultation with a rheumatologist.

Therefore, regarding laboratory data and histologic results pancreatic panniculitis was the only possible diagnosis.

Our case of pancreatic panniculitis is noteworthy for two reasons: The absence of pancreatic disease and the extrapancreatic manifestation of pancreatic-type ACC. The combination of both has not been previously described in the literature. Pancreatic panniculitis without definite proof of pancreatic disease is found in four cases in the literature: Beltraminelli et al. \[[@CR22]\] report a case of acinar cell cystadenocarcinoma of presumably pancreatic origin metastatic to the liver. However, clear evidence of a pancreatic primary tumor was absent on imaging. Freireich-Astmann et al. \[[@CR23]\] describe the history of a patient with hepatic metastases of an adenocarcinoma of unknown primary. CT did not show any pancreatic lesion and immunohistochemistry was negative for CA19-9 and CK19. Aznar-Oroval et al. present a case of gastric adenocarcinoma with hepatic metastases in association with pancreatic panniculitis, but without clinical or radiologic findings of pancreatic disease \[[@CR24]\]. And finally, Corazza et al. \[[@CR25]\] report about a patient with multifocal hepatocellular carcinoma (HCC) and missing pancreatic lesions in CT.

However, in all cases, no autopsy for definite verification of the absence of pancreatic disease was performed. Amylase or lipase were elevated in each of the cases, but could not be explained by clinical, radiologic or histological findings in all but Beltraminelli et al.'s case. While existence of a primary hepatic acinar cell cystadenocarcinoma should have been discussed in this case, findings are inconclusive in the other three.

The HCC described by Corazza showed "trabecular structures and acinar aspects", features suggestive of or consistent with ACC \[[@CR15]\]. As immunohistochemistry is not reported, the possibility of a pancreatic-type ACC of the liver cannot be fully excluded in that case.

Primary extrapancreatic ACC is extremely rare and only six cases of ACC originating in the liver have been described to date \[[@CR15], [@CR26], [@CR27]\]. Diagnosis of pancreatic-type ACC originating from the liver requires exclusion not only of an occult pancreatic primary, but also of primaries at other possible sites, such as breast \[[@CR28]\] or salivary glands \[[@CR29]\]. In our case, neither clinical nor radiological evidence for another primary was present, which was finally verified by autopsy findings. Moreover, re-analysis of the samples of the previously treated breast cancer excluded a hitherto undiscovered acinar cell carcinoma of the breast.

Because of the rarity of primary ACC of the liver, no typical pattern can be specified in the different imaging modalities up to now. So far, most of the cases described were initially misclassified as one of the most common primary liver malignancies, such as HCC or cholangiocellular carcinoma (CCC), due to their imaging appearance. Moreover, a recent study on imaging findings in pancreatic ACC also reported a high variability in several parameters analyzed \[[@CR30]\]. Thus, a thorough histological work-up of specimens after a resection or core biopsy is required to ensure the correct diagnosis \[[@CR15], [@CR26], [@CR27]\].

What could be objected to the diagnosis of an ACC of the liver in our case is the multifocality of the liver lesions, which is suggestive for metastatic disease. However, despite thorough work-up no other primary was found. Furthermore, it is worth noting that ACC is normally relatively large in size by the time of diagnosis \[[@CR4]\], which makes an occult primary rather unlikely. In addition, multifocal growth of primary liver tumors is not unusual, e.g. in intrahepatic CCC \[[@CR31], [@CR32]\] and HCC \[[@CR33], [@CR34]\]. Indeed, primary hepatic ACC might originate from acinar trans-differentiation of biliary progenitor cells, thus representing the acinar counterpart of hepatic cholangiocarcinoma \[[@CR15]\].

In an analysis of more than 130 cases of pancreatic panniculitis described in the last 20 years, we could show that nearly half of the cases are associated with an internal malignancy. Current concepts of the pathogenesis of pancreatic panniculitis suggest a role of pancreatic enzymes produced or released by these tumors \[[@CR8], [@CR9]\]. Therefore -- though only rarely so named \[[@CR35]\] -- pancreatic panniculitis should be regarded as facultative paraneoplastic condition \[[@CR36]\] and a tumor screening, especially for pancreatic tumors, should always be included in the diagnostic work-up.

The analysis of different parameters of these cases revealed significant differences between patients with pancreatic panniculitis and associated neoplasm or pancreatitis. On average, patients with a tumor are older and have higher lipase levels. Moreover, it takes longer until a diagnosis is made in these cases. A lipase cut-off value of 4414 U/l is able to differentiate between underlying pancreatitis and neoplasm with a sensitivity and specificity comparable with CA 19--9 in ductal adenocarcinoma vs. benign pancreatic disease \[[@CR37]\].

Regarding the epidemiology and the natural course of malignancy and pancreatitis these results are not very surprising. However, these items can provide a first orientation, which etiology has to be primarily suspected. Like this, they may trigger a particularly intensive search for tumors in older patients with high lipase levels and a long-lasting history of panniculitis.

This is even more important as pancreatic panniculitis seems to be a hallmark of poor prognosis in tumor patients. Median survival in the cases with underlying malignancy and included follow-up data was 4.75 months after appearance of the first skin lesion.

Of course, this retrospective analysis has significant limitations as it is exclusively based on case reports. Though, it is the first systematic evaluation of survival in pancreatic panniculitis and poor outcome is remarkable, because over 50 % of the included cases were ACC patients, which otherwise have considerably better survival \[[@CR38], [@CR39]\].

Due to the rarity of the disease, clear therapeutic algorithms for ACC are missing. Since most of the cases present with distant metastases only a subset of patients qualifies for resection \[[@CR39]\]. Therefore, cancer therapy is often limited to palliative approaches like chemotherapy or ablative treatment. As in our case, patients often suffer heavily from the pain caused by their skin lesions and analgetic therapy is frequently not sufficiently able to reduce pain \[[@CR12], [@CR14], [@CR22], [@CR40], [@CR41]\]. Thus, palliative treatment strategies are very important for symptom control as well.

Octreotide has been reported to alleviate symptoms in some cases \[[@CR42]--[@CR44]\]. Chemotherapeutic agents reported to be used in patients with pancreatic panniculitis and underlying ACC include gemcitabine and the FOLFIRI regime \[[@CR45], [@CR46]\]. Furthermore, one case with resolution of panniculitis following metastasectomy \[[@CR47]\] and one case with marked symptom reduction after transarterial chemoembolization (TACE) of hepatic metastases \[[@CR48]\] are described in literature. Some success in the treatment of pancreatic ACC has been reported with the use of FOLFOX \[[@CR49]\], FOLFIRINOX \[[@CR50]\], cisplatin/etoposide \[[@CR51]\] and gemcitabine in various combinations including erlotinib \[[@CR52]\].

Conclusion {#Sec6}
==========

To our best knowledge, this is the first report of pancreatic panniculitis in a patient with primary ACC of the liver.

The possibility of pancreatic panniculitis should always be included in diagnostic considerations regarding panniculitic lesions. Therefore, a cutaneous biopsy should be obtained, pancreatic enzymes should be measured and abdominal imaging should be performed as early as possible. When diagnosed, pancreatic panniculitis has to be regarded as a facultative paraneoplastic syndrome and appropriate tumor screening or biopsy procedures have to be undertaken. This is especially important in older patients with high lipase levels and long-lasting symptoms. Regarding the presented case, tumors of extrapancreatic primary must also be considered.

Pancreatic-type ACC is the malignancy most often associated with pancreatic panniculitis. It can not only originate from the pancreas but also from the liver, which can be diagnosed, when other primary sites have been excluded.

Pancreatic panniculitis in association with malignancy seems to be linked with poor prognosis. Thus, early diagnosis is necessary to improve survival and ease symptoms, e.g. by resection or chemotherapy. Symptomatic therapy with octreotide seems worth trying. Further studies are required to define standard therapeutic strategies for unresectable ACC.

Consent {#Sec7}
=======

During her lifetime, the patient consented orally to the use of her patient history and all the related images and information for scientific purposes. After the patient's death her daughter gave written consent for the publication of the case.

ACC

:   acinar cell carcinoma

ACE

:   angiotensin-converting enzyme

AFP

:   alpha fetoprotein

ANA

:   anti-nuclear antibody

ANCA

:   anti-neutrophil cytoplasmatic antibody

AP

:   alkaline phosphatase

AST

:   aspartate transaminase

CA 19--9

:   carbohydrate antigen 19--9

CCC

:   cholangiocellular carcinoma

CEA

:   carcinoembryonic antigen

CK

:   cytokeratin

CRP

:   c-reactive protein

CT

:   computed tomography

ECOG

:   Eastern cooperative oncology group

EN

:   erythema nodosum

ESWL

:   extracorporal shock wave lithotripsy

f

:   female

FOLFIRI

:   folinic acid, 5-fluoruracil, irinotecan

FOLFIRINOX

:   folinic acid, 5-fluoruracil, irinotecan, oxaliplatin

FOLFOX

:   folinic acid, 5-fluoruracil, oxaliplatin

GGT

:   gamma glutamyl transferase

HCC

:   hepatocellular carcinoma

IPMN

:   intraductal papillar mucinous neoplasm

m

:   male

MRI

:   magnetic resonance imaging

n.r.

:   not reported

NEC

:   neuroendocrine carcinoma

NSAID

:   non-steroidal anti-inflammatory drugs

PPP syndrome

:   pancreatitis panniculitis polyarthritis syndrome

TACE

:   transarterial chemoembolization
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